Q-omics provides the consensus-scored NLRP13 profile across patient tissues and cancer cell-line models. NLRP13 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NLRP13 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, NLRP13 RNA expression shows 6,708 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, BRCA, and STAD as cancer lineages where NLRP13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP13 survival associations across molecular data types. NLRP13 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP13 RNA expression–survival associations across cancer types. High NLRP13 expression shows unfavorable associations in UCS, KIRC, DLBC, ACC, TGCT and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NLRP13 RNA expression.
This table summarizes NLRP13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NLRP13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP13 shows lower tumor expression in BRCA and higher tumor expression in PRAD, LUSC and KIRC. The BRCA box plot shows higher NLRP13 RNA expression in normal versus tumor tissue (log2 FC = −0.301, t-test p < 0.001).
This table shows molecular features associated with NLRP13 in patient tissues and cancer cell lines. In patient samples, NLRP13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
